The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) given to adolescents with obesity was associated with a one-third ...

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session.

Recent data reveals that the eurozone economy has narrowly skirted a recession, showing lukewarm yet positive growth. With ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

As Wes Streeting suggests new weight-loss jabs could be given to unemployed people to help them get back into work, doctors ...

Wegovy, produced by Danish drugmaker Novo Nordisk, made a debut here on Tuesday, 16 months after the drug obtained regulatory ...

Weight loss drugs such as Wegovy have risen in popularity in recent months - but how exactly does it work and what are the side effects?

Wockhardt seeks approval for fast-acting insulin Aspart injection, showcasing end-to-end capabilities in biosimilar development for diabetes care.

Hims stock has rallied almost 22% this week on enthusiasm after the FDA said it will allow compounded versions of Lilly's ...

The UK Government is considering using weight-loss drugs to help support obese people in returning to work and reduce the high rates of long-term sickness, which have become a significant strain on ...

Health Secretary Wes Streeting believes these medications could be "life-changing" for individuals struggling with obesity.